Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Busy Week For Japanese Firm Otsuka: Justice Dept. Settlement For Off-Label Abilify Marketing And New Partnership With MethylGene

This article was originally published in PharmAsia News

Executive Summary

Abilify developer Otsuka Pharmaceutical settled with the U.S. Department of Justice over charges the company illegally marketed the atypical antipsychotic off-label for pediatric and elderly populations in the U.S. from 2002 through 2005
Advertisement

Related Content

Japan’s MHLW Designates Three Drugs As Orphan Drugs
Advertisement
UsernamePublicRestriction

Register

SC068066

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel